Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative Science from CALGB 80802
- Citation:
- J Clin Oncol vol 39 (3_suppl) 343
- Meeting Instance:
- ASCO GI 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 4010
- Pharmas:
- Bayer
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Laurent Dercle Susan Geyer Andrew Nixon Federico Innocenti Qian Shi Sawyer B. Jacobson Lyndon Luk Andrew Liu Hao Yang Yujia Wen Binsheng Zhao Monica M. Bertagnolli Jeffrey Meyerhardt Eileen M. O'Reilly Alan P. Venook Lawrence H. Schwartz Ghassan K. Abou-Alfa
- Networks:
- CA136, COLUMBIA, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016
- Study
- CALGB-80802
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: